Categories LATEST, Other Industries
Celgene gets a booster shot from recent positive clinical trial results
Troubled pharma giant Celgene (CELG) has announced 3 positive clinical trial results in the past two weeks. Today, the company reported positive results for its Phase III study of a breast cancer treatment, which was sponsored by Roche. Celgene, along with Acceleron Pharma (XLRN), had reported positive results recently in other two clinical trials.
“The IMpassion130 results are extremely encouraging for patients with this highly aggressive form of breast cancer for which there are limited options,” said CMO Jay Backstrom. According to the American Cancer Society, it is projected that 266,120 women in the US will be diagnosed with invasive breast cancer and 40,920 women will die because of it in 2018.
Related: Celgene plunges to a new 52-week low
On Monday, Celgene and Acceleron reported that blood-disorder drug Luspatercept met the endpoints of Phase III study. On June 28, both the companies announced that Luspatercept met the endpoints in the treatment of beta-thalassaemia study. The companies plan to apply for regulatory approvals for Luspatercept in the US and Europe during the first six months of 2019.
Celgene will be discussing the data from all these three clinical trials in the upcoming medical meetings in this year.
Celgene stock rose 2% in the pre-market trading session and continued to trade in the positive territory when the market opened today. Shares of Celgene, which hit its yearly low on May 21, were trading between $74.13 and $147.17 in the past one year and plunged about 20% so far this year.
Related: Celgene inks a deal with Skyhawk Therapeutics
Meanwhile, Acceleron stock was up 3% today. It’s worth noting that shares of Acceleron have skyrocketed 44% and Celgene shares climbed 10% after their announcement on June 28.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to